TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:March 3, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:March 3, 2023Recruiting
Condition(s):Neovascular Age-Related Macular DegenerationLast Updated:January 26, 2024Completed
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:November 2, 2023Active, not recruiting
Condition(s):Neovascular Age-related Macular Degeneration (nAMD)Last Updated:February 6, 2024Recruiting
Condition(s):Neovascular Age-Related Macular DegenerationLast Updated:January 19, 2023Terminated
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:May 23, 2023Completed
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:April 13, 2023Completed
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:January 18, 2024Recruiting
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:February 6, 2024Completed
Condition(s):Neovascular Age Related Macular DegenerationLast Updated:February 24, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.